https://scholars.lib.ntu.edu.tw/handle/123456789/628059
標題: | Erratum: ‘Corrigendum to “2017 Taiwan lipid guidelines for high risk patients” [Journal of the Formosan Medical Association (2017) [217–248]’(S0929664616304302)(10.1016/j.jfma.2016.11.013) | 作者: | Li, Yi-Heng Ueng, Kwo-Chang JIANN-SHING JENG Charng, Min-Ji TSUNG-HSIEN LIN KUO-LIONG CHIEN CHIH-YUAN WANG Chao, Ting-Hsing Liu, Ping-Yen Su, Cheng-Huang Chien, Shih-Chieh Liou, Chia-Wei SUNG-CHUN TANG Lee, Chun-Chuan Yu, Tse-Ya Chen, Jaw-Wen CHAU-CHUNG WU Yeh, Hung-I |
公開日期: | 八月-2018 | 出版社: | ELSEVIER TAIWAN | 卷: | 117 | 期: | 8 | 起(迄)頁: | 749 | 來源出版物: | Journal of the Formosan Medical Association = Taiwan yi zhi | 摘要: | In the page 225, left column, lines 3–7 of the article cited above, the sentence “The European Medicines Agency has approved alirocumab and evolocumab for patients who fail to achieve acceptable lipid control despite optimal statin therapy, patients with homozygous FH (HoFH), and statin-intolerant patients”, should have read “The European Medicines Agency has approved alirocumab and evolocumab for patients who fail to achieve acceptable lipid control despite optimal statin therapy, patients with homozygous FH (HoFH; evolocumab only), heterozygous FH, and statin-intolerant patients.” The authors would like to apologize for any inconvenience caused. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/628059 | ISSN: | 0929-6646 | DOI: | 10.1016/j.jfma.2018.07.007 |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。